Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Increasingly, services for the management of substance use disorders have been developed or adapted for remote delivery. Limited research has investigated service user experience of these services. We undertook a qualitative sub-study, embedded within a pilot feasibility study of remote symptom-triggered alcohol withdrawal management, to better understand the experiences of participants. Our aim was to determine the acceptability of the intervention and refine intervention procedures.

Methods: Eligible participants were enrolled in the parent study and completed at least one day of telemedicine-delivered symptom-triggered alcohol withdrawal management. Individuals were adults with alcohol use disorder recruited using intensity sampling. Participants completed an audio-recorded, semi-structured interview. Thematic analysis was conducted using Braun and Clarke interpretive methodology.

Results: Fourteen individuals were enrolled in the study. Six themes were identified: benefits of being in the home environment, technological tensions, intervention-specific feedback, personal motivations for participation, post-program achievements and changes and navigating the 'system'. Participants identified numerous benefits of being in the home environment including: increased comfort, privacy and security, normalizing abstinence in the home, flexibility to engage in other tasks, and the convenience of not travelling. Intervention-specific feedback included positive aspects of the intervention (interactions with staff, accountability, counselling, use of medication), areas for improvement (preparation, scheduling, medication logistics, and aftercare), and the meaning and role of having a support person available during treatment.

Conclusion: Participants found remote alcohol withdrawal management to be satisfactory and associated with several benefits including increased comfort, privacy, normalizing abstinence in the home, flexibility and convenience. They also provided important feedback for refinement of the intervention. Findings suggest that remote alcohol withdrawal management could play an important role in improving access to medical management of alcohol withdrawal, particularly in rural, remote or underserved areas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345073PMC
http://dx.doi.org/10.1186/s13722-025-00585-8DOI Listing

Publication Analysis

Top Keywords

alcohol withdrawal
24
withdrawal management
20
symptom-triggered alcohol
12
service user
8
benefits environment
8
intervention-specific feedback
8
including increased
8
increased comfort
8
comfort privacy
8
normalizing abstinence
8

Similar Publications

Therapeutic Potential of Agmatine in Alcohol Use Disorder: Preclinical insights and future directions.

Behav Brain Res

September 2025

Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, MS 441 002, India. Electronic address:

Alcohol Use Disorder (AUD) is a major global health challenge characterized by the recurrence of alcohol consumption, withdrawal symptoms, and significant social, economic, and health-related burdens. Despite conventional treatments such as cognitive behavioral therapy and medications like disulfiram and naltrexone, the majority of patients do not achieve adequate relief due to the multifactorial nature of this disorder, including mental health issues and neuroadaptive changes. Recent studies demonstrated that chronic alcohol consumption results in the disruption of both the production and signaling of endogenous agmatine, a neuromodulator synthesized from L-arginine.

View Article and Find Full Text PDF

Background And Objectives: Benzodiazepines are commonly prescribed medications approved for and used in the treatment of anxiolytic and sleep disorders, as well as for seizures, and alcohol withdrawal. However, benzodiazepines are also controlled substances because of their potential for abuse and personal harm, which are especially prevalent among older people. It is therefore important to understand how benzodiazepines are being prescribed, and the prevalence of off-label benzodiazepine prescribing, of which very little is known because of challenges in documenting treatment indication.

View Article and Find Full Text PDF

Alcohol use disorder-associated pain: clinical and preclinical evidence.

Alcohol

September 2025

School of Neuroscience, Virginia Polytechnic and State University, 970 Washington Street SW, Blacksburg, VA, 24061, USA. Electronic address:

Alcohol Use Disorder (AUD) affects millions of people globally and is characterized by cycles of intoxication, withdrawal, and relapse. Convergent clinical and preclinical evidence strongly support the conclusion that AUD precipitates chronic pain marked by mechanical and thermal hypersensitivity, yet currently available FDA-approved therapeutics do not effectively manage AUD-associated pain. This review synthesizes clinical and preclinical evidence on AUD-associated pain, highlighting known phenomena of allodynia and hyperalgesia as well as small and/or large fiber neuropathy in patient subpopulations along with preclinical acute and chronic alcohol exposure paradigm-specific nociceptive phenotypes in rodents.

View Article and Find Full Text PDF

Alcohol use disorder (AUD) is a mental disorder with a high prevalence and is one of the most common diagnoses requiring inpatient treatment. For the pharmacological management of withdrawal and detoxification, tranquilizing and anticonvulsant drugs, as well as symptom-triggered therapy, are recommended. In this study, we investigated the use of psychotropic drugs in the inpatient treatment of patients with AUD or acute intoxication by analyzing data from the Drug Safety Program in Psychiatry (German: Arzneimittelsicherheit in der Psychiatrie; AMSP).

View Article and Find Full Text PDF

Introduction: Through secondary data analyses, we investigated sex differences in the effects of IQOS, a heated tobacco product, on combustible cigarette smoking.

Methods: Adults who smoke cigarettes (N = 118; 21-65 years old) completed a baseline ad-lib smoking period (days 1-5), two laboratory visits (days 6-7), and a 14-day period where they were instructed to switch from smoking cigarettes to using IQOS 3.0 (days 8-21).

View Article and Find Full Text PDF